搜索结果
ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
---|
化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
---|
TCMBANKIN000094 | choline | Choline chloride; choline hydroxide | C5H14NO+ | 104.17 g/mol | C[N+](C)(C)CCO |
TCMBANKIN005364 | Phenylephrine | C9H13NO2 | 167.2 g/mol | CNCC(C1=CC(=CC=C1)O)O | |
TCMBANKIN013060 | coumarin,glycoside | 534.61 | |||
TCMBANKIN016334 | (-)-noradrenaline | to_000024; 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]-; KBio3_001579; CHEBI:18357; NCGC00159406-02; 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; Levoarterenol; KBio2_006625; KBio1_000230; L-Noradrenaline; NCGC00159406-05; Nor adrenalin (TN); Nor adrenalin; Noradrenaline (JP15); NINDS_000230; 4-[(1R)-2-amino-1-hydroxy-ethyl]pyrocatechol; Spectrum_001009; norepinephrinum; SPECTRUM1500436; KBio2_004057; Spectrum3_000520; KBio2_001489; DivK1c_000230; nchembio705-1; PDSP1_001111; 4-[(1R)-2-amino-1-hydroxy-ethyl]benzene-1,2-diol; 51-41-2; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-; KBioSS_001489; C00547; NCGC00159406-04; BSPBio_002079; AIDS335520; A7257_SIGMA; KBioGR_000635; D00076; (−)-Norepinephrine; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(-)-; Spectrum5_001068; Arterenol; Spectrum4_000078; PDSP2_001095; Spectrum2_001064; (-)-(R)-Norepinephrine; SGCUT00123; AIDS-335520; Norepinephrine (INN); SPBio_001048; IDI1_000230 | C8H11NO3 | 169.18 | C1=CC(=C(C=C1C(CN)O)O)O |
TCMBANKIN029162 | 18beta-glycyrrhetinic acid | AJ-72559; Rhetinic Acid; C02283; GLYCYRRHETINIC ACID; 18-beta-Glycyrrhetinic acid; 1449-05-4; Glycyrrhetic acid; Hidermart; CHEMBL230006; SMR000058239; SR-01000721867-5; NCGC00142473-03; 18beta-Glycyrrhetinic acid, purum, >=97.0% (T); UNII-P540XA09DR; Enoxolone (Glycyrrhetin); 107420-91-7; Enoxolone, Glycyrrhetinic acid; CCRIS 3962; LMPR0106150014; 18beta-Glycyrrhetic acid; 4-10-00-03775 (Beilstein Handbook Reference); BB_NC-0599; HMS2233P23; LS-7417; (3?)-3-Hydroxy-11-oxoolean-12-en-30-oic acid; Opera_ID_1048; D0U8IF; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; NSC-35350; Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo- (8CI); AC-1925; Glycyrrhetinic acid; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-2,4a,6a,6b,9,9,12a-heptamethyl-10-oxidanyl-13-oxidanylidene-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; HY-N0180; Arthrodont; Hidermart (TN); DTXSID9020669; SR-01000721867-3; MLS002207101; Enoxolona; Glycyrrhetinic acid (JAN); A-Hydroxy-11-oxoolean-12-en-30-olic acid; SR-01000721867-6; Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3beta,20beta)-; (3beta)-3-hydroxy-11-oxoolean-12-en-30-oic acid; subglycyrrhelinic acid; SCHEMBL18540; 471-53-4; Olean-12-en-30-oic acid, 3-beta-hydroxy-11-oxo-; BG01168029; FT-0082445; BX-1; Glycyrrhetin; D00156; NCGC00017244-03; 202522-39-2; 18-beta-Glycyrrhetic acid; SR-01000721867-4; Enoxolonum [INN-Latin]; SBB006496; GM-1658; Q-201057; NSC-35347; NSC 35347; (5S,8S,15S,18S,1R,2R,10R,14R,20R)-18-hydroxy-1,2,5,8,15,19,19-heptamethyl-13-o xopentacyclo[12.8.0.0<2,11>.0<5,10>.0<15,20>]docos-11-ene-8-carboxylic acid; alpha-Glycyrrhetinic acid; Tox21_112726; 130100-EP2295411A1; ZINC19203131; Biosone; D08LGJ; Bio-0549; Enoxolone; 18beta-Glycyrrhetinic acid; 3?-Hydroxy-11-oxo-18?,20?-olean-12-en-29-oic acid; Enoxolone (Glycyrrhetinic acid); 50510_FLUKA; BDBM50233538; Uralenic acid; NCGC00017244-04; P540XA09DR; 18beta-glycyrrhetic acid; C30H46O4; Jintan; Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo-; CAS-471-53-4; Tox21_200799; SR-01000721867; Enoxolone (INN); MLS001146949; MLS000028748; [(125)I] RB129; G10105_ALDRICH; (3beta,20beta)-3-Hydroxy-11-oxo-olean-12-en-29-oic acid; s2296; CCG-208506; 8055-71-8; EINECS 207-444-6; (2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid; Enoxolona [INN-Spanish]; GlycyrrhetinicAcid; 18b-Glycyrrhetic acid; AC1L1UIT; 130100-EP2269977A2; KS-1262; Glycyrrhetinate; Glycyrrhetinic acid [JAN]; (3alpha,5xi,8alpha,9xi,17alpha,18xi)-3-hydroxy-11-oxoolean-12-en-29-oic acid; BC201656; Enoloxone; Enoxolone [INN:BAN:DCF]; 18 beta-glycyrrhetinic acid; 3beta-Hydroxy-11-oxo-18beta,20beta-olean-12-en-29-oic acid; enoxolone; DSSTox_RID_75722; 18 beta-Glycyrrhetintic Acid; DSSTox_CID_669; 3-Glycyrrhetinic acid; 3beta-hydroxy-11-oxoolean-12-en-29-oic acid; NCGC00181115-01; Enoxolone; STX-352; AKOS016036757; 15301-63-0; G0149; MFCD00003706; ST24038257; Enoxolone, European Pharmacopoeia (EP) Reference Standard; ST056310; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-13-keto-2,4a,6a,6b,9,9,12a-heptamethyl-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; AKOS015960428; 471G534; NCGC00258353-01; DB13089; Tox21_110804; CBW; DSSTox_GSID_20669; D0F6IV; MolPort-002-507-130; A827163; (3beta,5beta,14beta)-3-Hydroxy-11-Oxoolean-12-En-29-Oic Acid; 18beta-Glycyrrhetinic acid, 97%; CHEBI:30853; AC-8906; AN-14462; API0002854; BRN 2229654; Glyciram; 18beta-Glycyrrhetinic acid; MCULE-4676598997; 3beta-Hydroxy-11-oxoolean-12-en-30-oic acid; 3-beta-Hydroxy-11-oxoolean-12-en-30-oic acid; BG00824432; Enoxolone [BAN:DCF:INN]; CS-W020624; S00284; Enoxolonum; 299198-00-8 | C30H46O4 | 470.68 | CC1(C2CCC3(C(C2(CCC1O)C)C(=O)C=C4C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C |
TCMBANKIN029777 | vitamin d3 | C28H46O | 398.7 g/mol | CC(C)C(C)CCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C | |
TCMBANKIN031363 | dimethyl sulfoxide | C2H6OS | 78.14 g/mol | CS(=O)C | |
TCMBANKIN033702 | citric acid | InChI=1/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12; NCGC00090954-02; NCGC00090954-01; HSDB 911; CIT; Citric acid (8CI); BRN 0782061; NCIStruc2_000099; 27109_RIEDEL; AIDS-017733; 1,2,3-PROPANETRICARBOXYLIC ACID,2-HYDROXY (CITRIC ACID); citr; 27488_FLUKA; FEMA No. 2306; E 330; 27485_FLUKA; 27487_FLUKA; 77-92-9; C2404_SIGMA; 2-Hydroxytricarballylic acid; NCIOpen2_004502; F 0001 (polycarboxylic acid); EPA Pesticide Chemical Code 021801; AI3-06286; 245654-34-6; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; Citretten; Kyselina citronova; 2-hydroxypropane-1,2,3-tricarboxylic acid; Anhydrous citric acid; Citrate standard for IC; C83155_SIAL; LS-2418; WLN: QV1XQVQ1VQ; 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI); NSC30279; .beta.-Hydroxytricarballylic acid; NSC 626579; FLC; NCI60_022579; LS-3185; 2-hydroxy-1,2,3-propanetricarboxylic acid; Caswell No. 221C; EINECS 201-069-1; 43136-35-2; 251275_SIAL; 38730_FLUKA; C4540_SIGMA; FEMA Number 2306; 4-03-00-01272 (Beilstein Handbook Reference); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; Citric acid anhydrous (JAN); C00158; 12262-73-6; 240621_ALDRICH; AIDS017733; MLS001066346; Kyselina 2-hydroxy-1,2,3-propantrikarbonova [Czech]; 2-Hydroxypropanetricarboxylic acid; CCRIS 3292; KBio3_002740; NSC626579; D00037; SBB008922; Kyselina citronova [Czech]; Aciletten; NSC 30279; Anhydrous citric acid (JP15); 46933_SUPELCO; NCIOpen2_004062; Citric acid solution; CHEBI:30769; Citro; BSPBio_003240; NCIStruc1_000057; Uro-trainer; Citric acid, anhydrous (USP); W230618_ALDRICH; Citric acid [USAN:JAN]; H3cit; Chemfill; Hydrocerol A; Suby G; Oprea1_502996; Citric acid, anhydrous; SMR000471840; Citric acid anhydrous; Spectrum3_001850 | C6H8O7 | 192.12 | C(C(=O)O)C(CC(=O)O)(C(=O)O)O |
TCMBANKIN034198 | acetic acid | AI3-02394; NSC132953; Azijnzuur [Dutch]; Acido acetico [Italian]; Essigsaeure [German]; InChI=1/C2H4O2/c1-2(3)4/h1H3,(H,3,4; Pyroligneous acid; CARBOXYMETHYL GROUP; Caswell No. 003; 45727_FLUKA; A8976_SIAL; A6283_SIAL; 64-19-7; BRN 0506007; 318590_ALDRICH; 45730_FLUKA; 77671-22-8; cellulose diacetate; Acetic acid solution, with more than 10% and less than 50% acid, by mass [UN2790] [Corrosive]; 9035-69-2; 49199_FLUKA; Cellulose diacetate [USAN]; Cellulose, diacetate; FEMA Number 2006; W200611_ALDRICH; CBM; 320099_SIAL; Methanecarboxylic acid; 45726_FLUKA; NCIOpen2_000682; Glacial acetic acid; Acetic acid (JP15/NF); ethanoic acid; 207004-55-5; Otic Tridesilon; 40209_RIEDEL; Acetic acid, propionic acid distillate; NSC406306; 537020_SIAL; 45725_FLUKA; WLN: QV1; LS-2535; Acetic acid, glacial; 27225_RIEDEL; Ethylic acid; AKOS006290339; 07692_FLUKA; ACY; NSC 132953; ACT; 33206_RIEDEL; EPA Pesticide Chemical Code 044001; 380121_SIAL; W200603_ALDRICH; Acetic acid, glacial (USP); ethoic acid; Acetic acid, glacial or acetic acid solution, >80% acid, by mass [UN2789] [Corrosive]; 34254_RIEDEL; 4-02-00-00094 (Beilstein Handbook Reference); 46928_SUPELCO; Acido acetico; C00033; Acetasol (TN); Acetic acid solution, not less than 50% but more than 80% acid, by mass [UN2790] [Corrosive]; Carboxylic acids, C2-3; CHEBI:15366; Acetic acid, of a concentration of more than 10 per cent, by weight, of acetic acid; 45732_FLUKA; Acetic acid [JAN]; Octowy kwas [Polish]; Essigsaeure; Vinegar acid; 242853_SIAL; Glacial acetic acid (JP15); 38050_RIEDEL; A9967_SIAL; LS-1541; 38051_RIEDEL; Kyselina octova [Czech]; ST5213882; Acetate standard for IC; 33209_RIEDEL; UN2790; 40273_RIEDEL; Azijnzuur; Acetic acid solution; Acetic acid (natural); D00010; LMFA01010002; 27218_RIEDEL; Acetic acid, aqueous solution; HSDB 40; 68475-71-8; 34255_RIEDEL; NCIOpen2_000659; 34256_RIEDEL; FEMA No. 2006; CCRIS 5952; Acide acetique; Acetic acid, diluted; Acetasol; Octowy kwas; 71251_FLUKA; 338826_SIAL; EINECS 200-580-7; 13669_FLUKA; Acide acetique [French]; CH3-COOH; 45754_FLUKA; 157090-22-7; Acetic acid, water solutions; UN2789 | C5H10O3 | 118.13 | CC(=O)NCCC1=CN(C2=C1C=C(C=C2)OC)C(=O)C3=CC=C(C=C3)Cl |
TCMBANKIN044431 | Momordin IIc | 927 | |||
TCMBANKIN057947 | glucoside | SCHEMBL25601; FT-0626726; 136760-05-9; .beta.-D-Glucose; UNII-J4R00M814D; beta-glucose; 207381-EP2280021A1; 133947-06-5; beta-delta-Glucopyranose; MCULE-4260589665; CHEBI:15903; beta-d-(+)-glucose; BDBM50240803; 28905-12-6; MolPort-006-111-449; KB-277820; DB02379; D07ONX; 6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetrol; SC-25121; NSC759603; (1->6)-beta-D-glucopyranan; 1,2-beta-D-Glucan; EINECS 207-756-2; beta-D-Glc; (1,2-beta-D-glucosyl)n; (2R,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; .beta.-D-Glucopyranose; FT-0622903; NSC-759603; Beta-D-glucose anhydrous; b-D-Glucopyranose; CHEMBL1614854; beta-D-glucopyranose; W-202206; 1,5]; AC1L21QQ; C00221; Grape sugar; BG01505598; Galactitol,1,5-anhydro-1-C-phenyl-; G0047; 53991-51-8; 492-61-5; b-d-glucose; 9001-37-0; BGC; WQZGKKKJIJFFOK-VFUOTHLCSA-N; (1->3)-beta-D-glucan; CTK8F0914; AKOS016010209; DB-051616; AE-562/43459286; 207381-EP2280004A1; 50986-29-3; AK306225; (1->3)-beta-D-glucopyranan; TR-038298; beta-(1,3)-glucan; Curdlan; b-Glucose; .beta.-d-Glucose, anhydrous; ZINC3833800; CHEBI:27517; CHEBI:37671; FCH1120200; beta-Dextrose; (1->4)-beta-D-glucopyranan; (1->6)-beta-D-glucan; WURCS=1.0/1,0/[12122h; beta-D-glucose; (2R,3R,4S,5R,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; (1->2)-beta-D-glucopyranan; Pharmakon1600-01300015; ZYMOSAN; AJ-45802; (+)-Glucose; CHEBI:18246; 207381-EP2280020A1; (1->2)-beta-D-glucan; b-Dextrose; 108942-17-2; (2R,3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; MFCD00063989; 492-64-8; CHEBI:27380; (1->4)-beta-D-glucan; anhydrous glucose; Glucose, (beta-D)-Isomer; J4R00M814D; Callose; beta-D-Glucopyranose, anhydrous; Beta-d-glucose, anhydrous; 128009-02-9; AX8115243;BGC | C6H12O6 | 180.16 g/mol | C(C1C(C(C(C(O1)O)O)O)O)O |
TCMBANKIN057949 | sucrose | Amerfand; 29253-78-9; Sucrose (TN); alpha-D-Glucopyranoside, beta-D-fructofuranosyl-; saccharose; Sugar, compressible (NF); S0389_SIGMA; D06530; C00089; 1-alpha-D-Glucopyranosyl-2-beta-D-fructofuranoside; Sucrose, purified; 8027-47-2; 30027-72-6; 29764-06-5; 86101-30-6; NSC 406942; D06529; Sucrose [USAN:JAN]; 146187-04-4; ST5308554; Sugar, confectioner's; D(+)-Saccharose; S7903_SIGMA; GLC-(1-2)FRU; alpha-D-glucopyranosyl beta-D-fructofuranoside; FICOLL; 151756-02-4; Sugar spheres (NF); White soft sugar (JP15); Sucraloxum [INN-Latin]; Saccharum; alpha-D-Glc-(1-2)-beta-D-Fru; S9378_SIGMA; 76056-38-7; 47289_SUPELCO; D-Sucrose; Sugar spheres; 87430-66-8; 104242-10-6; (alpha-D-Glucosido)-beta-D-fructofuranoside; Table sugar; Sacharose; (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2-yl]oxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; NCI-C56597; 47167-52-2; CCRIS 2120; alpha-D-Glucopyranoside, beta-D-fructofuranosyl, homopolymer; D06528; Microse; Cane sugar; Amerfond; 64533-66-0; White soft sugar; beta-D-Fruf-(2<->1)-alpha-D-Glcp; sugar; White sugar; SUC; 84097_FLUKA; Rock candy; beta-D-Fructofuranosyl-alpha-D-glucopyranoside; Fructofuranoside, alpha-D-glucopyranosyl, beta-D; 80165-03-3; 47257-91-0; CHEBI:17992; 47185-09-1; S5390_SIGMA; alpha-D-Glucopyranoside, beta-D-fructofuranosyl; S1888_SIGMA; 220376-22-7; D06533; 8030-20-4; S3929_SIGMA; S1174_SIGMA; 65545-99-5; Glucopyranoside, beta-D-fructofuranosyl, alpha-D; S2395_SIGMA; 78654-77-0; D06531; (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol; SUCROSE; S5016_SIAL; 51909-69-4; 85456-51-5; D()-Saccharose; ZINC04217475; 84100_FLUKA; D00025; Confectioner's sugar; EINECS 200-334-9; Sugar, confectioner's (NF); 57-50-1; 100405-08-1; 92004-84-7; Beet sugar; S5391_SIGMA; Sucrose, dust; alpha-D-Glc-(1->2)-beta-D-Fru; beta-D-Fructofuranosyl alpha-D-glucopyranoside; 131932-12-2; HSDB 500; Sugar, compressible; AI3-09085; alpha-D-Glucopyranosylbeta-D-fructofuranoside; Rohrzucker; 16104_RIEDEL; (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-dimethylol-tetrahydrofuran-2-yl]oxy-6-methylol-tetrahydropyran-3,4,5-triol; Granulated sugar; S8501_SIGMA; Sucrose, purified (JAN); 146054-35-5; Sucrose (JP15/NF); 9012-95-7; Sucrose, pure; 75398-84-4; 50857-68-6; (2R,3R,4S,5S,6R)-2-[[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)-2-tetrahydrofuranyl]oxy]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; 25702-74-3; D(+)-Sucrose | C12H22O11 | 342.3 g/mol | C(C1C(C(C(C(O1)OC2(C(C(C(O2)CO)O)O)CO)O)O)O)O |
TCMBANKIN058450 | ADO | nchembio.2007.56-comp13; CHEBI:16335; Bio1_000437; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; AIDS-001224; 9beta-D-Ribofuranosyladenine; BSPBio_001796; beta-Adenosine; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-methylol-tetrahydrofuran-3,4-diol; beta-D-Ribofuranoside, adenine-9; D00045; 46969-16-8; SDCCGMLS-0003108.P003; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; NSC 7652; Bio1_001415; Adenosine (JAN/USP); Spectrum2_001257; Spectrum3_000288; Adenosine, homopolymer; ADN; Caswell No. 010B; Adenocard; C00212; SR 96225; Adenocard (TN); EINECS 200-389-9; KBio3_001296; 9H-Purin-6-amine, 9beta-D-ribofuranosyl-; Polyadenosine; beta-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; (2R,3R,4S,5R)-2-(6-amino-9-purinyl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; MLS000069638; AI3-52413; 9-beta-D-Ribofuranosidoadenine; A9251_SIGMA; Adenoscan (TN); Bio1_000926; ZINC02169830; CCRIS 2557; NCGC00023673-05; Ade-Rib; nchembio706-5; 30143-02-3; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; Adenosin [German]; NSC 627048; SMR000058216; 9-beta-D-Ribofuranosyladenine; SPBio_001194; beta-D-Adenosine; Adenosine [USAN:BAN]; Polyriboadenosine; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; AIDS001224; 6-Amino-9beta-D-ribofuranosyl-9H-purine; ST009496; Adenoscan; A4036_SIGMA; SPECTRUM1500107; 46946-45-6;SCHEMBL170902; adenosine ; AKOS015960342; AC-5504; BC200893; Adenosine;adenosine;adeninenucleoside | C10H13N5O4 | 267.24 g/mol | C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N |
TCMBANKIN058990 | forskolin | coleonol | C22H34O7 | 410.5 g/mol | CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O |
TCMBANKIN059230 | isovalericacid | LS-2386; ST5213941; Iva; Butanoic acid , 3-methyl-; Butyric acid, 3-methyl-; Kyselina isovalerova [Czech]; W310212_ALDRICH; Isobutyl formic acid; beta-Methylbutyric acid; 92634-50-9; 503-74-2; CHEBI:28484; WLN: QV1Y1&1; EINECS 207-975-3; 3-Methylbutyrate; isovaleric acid; METHYLBUTANOIC ACID; 4-02-00-00895 (Beilstein Handbook Reference); InChI=1/C5H10O2/c1-4(2)3-5(6)7/h4H,3H2,1-2H3,(H,6,7; NSC62783; Isovaleric acid (natural); 3-Methylbuttersaeure; Delphinic acid; 129542_ALDRICH; AI3-24132; NSC 62783; Butanoic acid, 3-methyl-, (R)-; FEMA Number: 3102; 3-methyl-butanoic acid; Acetic acid, isopropyl-; Isovaleriansaeure; 3-Methylbutyric acid; C08262; 3,4-Diisovaleryl adrenaline; HSDB 629; Isovalerianic acid; .beta.-Methylbutyric acid; BRN 1098522; 59850_FLUKA; Isopropylacetic acid; LMFA01020181; Isobutylformic acid; FEMA No. 3102; Isovaleric acid; Butanoic acid, 3-methyl-; W310204_ALDRICH; Isopentanoic acid; Isovalerianic; 35915-22-1; 3-Methylbutanoic acid | C5H10O2 | 102.13 g/mol | CC(C)CC(=O)O |
TCMBANKIN060181 | azukisaponin v | C48H78O18 | 943.1 g/mol | CC1C(C(C(C(O1)OC2C(C(C(OC2OC3C(C(C(OC3OC4CCC5(C(C4(C)CO)CCC6(C5CC=C7C6(CCC8(C7CC(CC8O)(C)C)C)C)C)C)C(=O)O)O)O)CO)O)O)O)O)O | |
TCMBANKIN061383 | Phenylephrine | Carney glycosides | C9H13NO2 | 167.2 g/mol | CNCC(C1=CC(=CC=C1)O)O |
疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
---|
TCMBANKDI000009 | Neoplasms | Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
TCMBANKDI000023 | Skin and Connective Tissue Diseases; Immune System Diseases | Abnormality of the immune system | Disease or Syndrome | disease | |
TCMBANKDI000049 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
TCMBANKDI000076 | Neoplasms | - | Neoplastic Process | group | |
TCMBANKDI000092 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | disease | |
TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
TCMBANKDI000167 | Neoplasms | - | Neoplastic Process | phenotype | |
TCMBANKDI000673 | Respiratory Tract Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI000935 | Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
TCMBANKDI001068 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Respiratory Tract Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI001073 | Cardiovascular Diseases | Abnormality of the cardiovascular system | Finding | phenotype | |
TCMBANKDI001279 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Cardiovascular Diseases | Abnormality of the nervous system; Abnormality of blood and blood-forming tissues; Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
TCMBANKDI001299 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Cardiovascular Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
TCMBANKDI001412 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
TCMBANKDI001706 | Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Disease or Syndrome | disease | |
TCMBANKDI002162 | - | - | Disease or Syndrome | disease | |
TCMBANKDI002168 | - | - | Disease or Syndrome | disease | |
TCMBANKDI002525 | Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
TCMBANKDI002742 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | group | |
TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
TCMBANKDI003037 | Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Sign or Symptom | phenotype | |
TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
TCMBANKDI003261 | - | Abnormality of the skeletal system | Anatomical Abnormality | disease | |
TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
TCMBANKDI003411 | - | - | Disease or Syndrome | disease | |
TCMBANKDI003574 | Cardiovascular Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI003692 | - | - | Disease or Syndrome | disease | |
TCMBANKDI003829 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Eye Diseases; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI004054 | Pathological Conditions, Signs and Symptoms | - | Neoplastic Process | phenotype | |
TCMBANKDI004086 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
TCMBANKDI004508 | Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases | Abnormality of the integument; Abnormality of connective tissue | Acquired Abnormality | disease | |
TCMBANKDI004520 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI004576 | Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
TCMBANKDI005528 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Nervous System Diseases | - | Congenital Abnormality | disease | |
TCMBANKDI006055 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | disease | |
TCMBANKDI006154 | Digestive System Diseases | Abnormality of the digestive system | Disease or Syndrome | disease | |
TCMBANKDI006328 | - | Abnormality of the genitourinary system | Disease or Syndrome | phenotype | |
TCMBANKDI006612 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
TCMBANKDI006860 | - | - | Diagnostic Procedure | phenotype | |
TCMBANKDI007189 | Endocrine System Diseases | Abnormality of the endocrine system | Disease or Syndrome | group | |
TCMBANKDI007281 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
TCMBANKDI007520 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
TCMBANKDI007765 | Digestive System Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI007832 | Cardiovascular Diseases | - | Disease or Syndrome | phenotype | |
TCMBANKDI007898 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI008043 | Cardiovascular Diseases | Abnormality of the cardiovascular system | Anatomical Abnormality | disease | |
TCMBANKDI008305 | Digestive System Diseases; Infections | Abnormality of the digestive system; Abnormality of the immune system | Disease or Syndrome | group | |
TCMBANKDI008314 | Eye Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI008698 | - | - | Congenital Abnormality | disease | |
TCMBANKDI008766 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Congenital Abnormality | disease | |
TCMBANKDI009099 | Nutritional and Metabolic Diseases; Endocrine System Diseases | - | Experimental Model of Disease | disease | |
TCMBANKDI009231 | Pathological Conditions, Signs and Symptoms; Infections | Abnormality of the immune system | Disease or Syndrome | disease | |
TCMBANKDI009424 | Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
TCMBANKDI009470 | Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI009657 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases | Abnormality of the cardiovascular system | Congenital Abnormality | group | |
TCMBANKDI009680 | Respiratory Tract Diseases; Immune System Diseases | Abnormality of the respiratory system | Disease or Syndrome | group | |
TCMBANKDI009702 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | phenotype | |
TCMBANKDI009722 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | - | Pathologic Function | phenotype | |
TCMBANKDI009869 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Cardiovascular Diseases | Abnormality of the nervous system; Abnormality of the cardiovascular system | Disease or Syndrome | phenotype | |
TCMBANKDI009912 | Pathological Conditions, Signs and Symptoms | Abnormality of metabolism/homeostasis | Sign or Symptom | phenotype | |
TCMBANKDI009951 | Nutritional and Metabolic Diseases; Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
TCMBANKDI010048 | Infections; Respiratory Tract Diseases | Abnormality of the immune system; Abnormality of the respiratory system | Disease or Syndrome | disease | |
TCMBANKDI010160 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | group | |
TCMBANKDI010968 | Nervous System Diseases; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
TCMBANKDI011083 | Pathological Conditions, Signs and Symptoms | - | Sign or Symptom | group | |
TCMBANKDI011173 | Neoplasms | - | Neoplastic Process | disease | |
TCMBANKDI011174 | Infections | - | Disease or Syndrome | group | |
TCMBANKDI011393 | Digestive System Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI011458 | Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI011779 | - | Abnormality of the skeletal system | Anatomical Abnormality | disease | |
TCMBANKDI012157 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | group | |
TCMBANKDI012234 | Female Urogenital Diseases and Pregnancy Complications; Infections; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI012952 | - | Abnormality of the immune system; Abnormality of the eye | Disease or Syndrome | disease | |
TCMBANKDI013075 | Cardiovascular Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI013240 | Nervous System Diseases; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI013347 | Pathological Conditions, Signs and Symptoms | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
TCMBANKDI013453 | Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of metabolism/homeostasis; Abnormality of the genitourinary system | Finding | phenotype | |
TCMBANKDI013541 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
TCMBANKDI013599 | - | Growth abnormality | Disease or Syndrome | phenotype | |
TCMBANKDI013730 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases | Abnormality of the cardiovascular system | Congenital Abnormality | disease | |
TCMBANKDI013927 | Respiratory Tract Diseases | Abnormality of the respiratory system | Pathologic Function | phenotype | |
TCMBANKDI014161 | Stomatognathic Diseases | Abnormality of the immune system; Abnormality of head or neck | Disease or Syndrome | group | |
TCMBANKDI014342 | Behavior and Behavior Mechanisms | - | Mental or Behavioral Dysfunction | phenotype | |
TCMBANKDI014511 | - | - | Mental or Behavioral Dysfunction | disease | |
TCMBANKDI014688 | Endocrine System Diseases | Abnormality of the endocrine system | Disease or Syndrome | phenotype | |
TCMBANKDI014716 | Nervous System Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI014740 | Pathological Conditions, Signs and Symptoms | Abnormality of the digestive system | Disease or Syndrome | phenotype | |
TCMBANKDI014941 | Eye Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI014969 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI015238 | Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI015336 | - | - | Disease or Syndrome | phenotype | |
TCMBANKDI015485 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
TCMBANKDI015660 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI015829 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
TCMBANKDI016425 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Immune System Diseases | Abnormality of the genitourinary system; Abnormality of the immune system | Disease or Syndrome | disease | |
TCMBANKDI016612 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | phenotype | |
TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
TCMBANKDI017267 | Endocrine System Diseases | Abnormality of the endocrine system | Disease or Syndrome | disease | |
TCMBANKDI017381 | Endocrine System Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI017383 | Eye Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI017673 | - | - | Clinical Attribute | phenotype | |
TCMBANKDI018055 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Endocrine System Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI018731 | Digestive System Diseases | Abnormality of the digestive system | Disease or Syndrome | disease | |
TCMBANKDI019650 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | - | Disease or Syndrome | phenotype | |
TCMBANKDI019825 | Neoplasms | - | Neoplastic Process | disease | |
TCMBANKDI020257 | Cardiovascular Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI020285 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI020602 | Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
TCMBANKDI020794 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
TCMBANKDI020912 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI021005 | Cardiovascular Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI021293 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Cardiovascular Diseases | Abnormality of the genitourinary system; Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
TCMBANKDI021831 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the endocrine system | Disease or Syndrome | disease | |
TCMBANKDI021906 | - | - | Disease or Syndrome | disease | |
TCMBANKDI022361 | Pathological Conditions, Signs and Symptoms; Eye Diseases | - | Sign or Symptom | phenotype | |
TCMBANKDI022433 | Respiratory Tract Diseases; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI022473 | Neoplasms | - | Neoplastic Process | disease | |
TCMBANKDI022757 | Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI023140 | Neoplasms; Endocrine System Diseases | Abnormality of the endocrine system; Neoplasm | Neoplastic Process | disease | |
TCMBANKDI023160 | Digestive System Diseases; Neoplasms | - | Disease or Syndrome | disease | |
TCMBANKDI023464 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
TCMBANKDI024875 | Nutritional and Metabolic Diseases; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI025090 | Pathological Conditions, Signs and Symptoms; Respiratory Tract Diseases | Abnormality of the respiratory system | Sign or Symptom | phenotype | |
TCMBANKDI025265 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Stomatognathic Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI025337 | - | - | Disease or Syndrome | phenotype | |
TCMBANKDI025399 | Cardiovascular Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI025420 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
TCMBANKDI025502 | - | - | Laboratory Procedure | phenotype | |
TCMBANKDI025794 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Endocrine System Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI026193 | Endocrine System Diseases; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI026399 | - | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
TCMBANKDI026556 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
TCMBANKDI027014 | Cardiovascular Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI027339 | Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | disease | |
TCMBANKDI027628 | Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI028111 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI028561 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Neoplastic Process | disease | |
TCMBANKDI028571 | - | - | Congenital Abnormality | disease | |
TCMBANKDI028744 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | phenotype | |
TCMBANKDI028908 | Pathological Conditions, Signs and Symptoms; Eye Diseases; Nervous System Diseases | Abnormality of the eye | Disease or Syndrome | phenotype | |
TCMBANKDI028919 | - | - | Congenital Abnormality | disease | |
TCMBANKDI029038 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases | - | Disease or Syndrome; Congenital Abnormality | disease | |
TCMBANKDI029321 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
TCMBANKDI029791 | Nutritional and Metabolic Diseases | - | Disease or Syndrome | phenotype | |
TCMBANKDI030537 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
TCMBANKDI030829 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI031192 | Neoplasms; Male Urogenital Diseases | - | Neoplastic Process | disease | |
TCMBANKDI031297 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
TCMBANKDI032222 | Nervous System Diseases; Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
TCMBANKDI032321 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Endocrine System Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI032496 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
TCMBANKDI032498 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease |